Miladi Imen, Alric Christophe, Dufort Sandrine, Mowat Pierre, Dutour Aurélie, Mandon Céline, Laurent Gautier, Bräuer-Krisch Elke, Herath Nirmitha, Coll Jean-Luc, Dutreix Marie, Lux François, Bazzi Rana, Billotey Claire, Janier Marc, Perriat Pascal, Le Duc Géraldine, Roux Stéphane, Tillement Olivier
Laboratoire de Physico-Chimie des Matériaux Luminescents, UMR 5620 CNRS - UCBL, Université de Lyon, Villeurbanne, 69622, France.
Small. 2014 Feb 4. doi: 10.1002/smll.201302303.
Owing to the high atomic number (Z) of gold element, the gold nanoparticles appear as very promising radiosensitizing agents. This character can be exploited for improving the selectivity of radiotherapy. However, such an improvement is possible only if irradiation is performed when the gold content is high in the tumor and low in the surrounding healthy tissue. As a result, the beneficial action of irradiation (the eradication of the tumor) should occur while the deleterious side effects of radiotherapy should be limited by sparing the healthy tissue. The location of the radiosensitizers is therefore required to initiate the radiotherapy. Designing gold nanoparticles for monitoring their distribution by magnetic resonance imaging (MRI) is an asset due to the high resolution of MRI which permits the accurate location of particles and therefore the determination of the optimal time for the irradiation. We recently demonstrated that ultrasmall gold nanoparticles coated by gadolinium chelates (Au@DTDTPA-Gd) can be followed up by MRI after intravenous injection. Herein, Au@DTDTPA and Au@DTDTPA-Gd were prepared in order to evaluate their potential for radiosensitization. Comet assays and in vivo experiments suggest that these particles appear well suited for improving the selectivity of the radiotherapy. The dose which is used for inducing similar levels of DNA alteration is divided by two when cells are incubated with the gold nanoparticles prior to the irradiation. Moreover, the increase in the lifespan of tumor bearing rats is more important when the irradiation is performed after the injection of the gold nanoparticles. In the case of treatment of rats with a brain tumor (9L gliosarcoma, a radio-resistant tumor in a radiosensitive organ), the delay between the intravenous injection and the irradiation was determined by MRI.
由于金元素的高原子序数(Z),金纳米颗粒似乎是非常有前景的放射增敏剂。这一特性可用于提高放射治疗的选择性。然而,只有当肿瘤中的金含量高而周围健康组织中的金含量低时进行照射,这种提高才有可能实现。因此,在根除肿瘤的同时,应通过保护健康组织来限制放射治疗的有害副作用。因此,需要放射增敏剂的定位来启动放射治疗。由于磁共振成像(MRI)具有高分辨率,能够精确确定颗粒的位置,从而确定最佳照射时间,因此设计用于通过MRI监测其分布的金纳米颗粒是一项优势。我们最近证明,静脉注射后,钆螯合物包被的超小金纳米颗粒(Au@DTDTPA-Gd)可通过MRI进行追踪。在此,制备了Au@DTDTPA和Au@DTDTPA-Gd,以评估它们的放射增敏潜力。彗星试验和体内实验表明,这些颗粒似乎非常适合提高放射治疗的选择性。当细胞在照射前与金纳米颗粒一起孵育时,用于诱导相似水平DNA改变的剂量减半。此外,在注射金纳米颗粒后进行照射时,荷瘤大鼠的寿命延长更为显著。在治疗患有脑肿瘤(9L胶质肉瘤,一种位于放射敏感器官中的放射抗性肿瘤)的大鼠时,通过MRI确定静脉注射与照射之间的延迟。